Standardization and characterization of the procedure forin vitrotreatment of human bone marrow with cyclophosphamide derivatives
- 1 December 1985
- journal article
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 7 (4) , 327-334
- https://doi.org/10.1111/j.1365-2257.1985.tb00047.x
Abstract
Summary Thirty human bone marrow (BM) suspensions from patients with acute leukaemia patients in remission were processed with the Haemonetics 30 flow cell separator in order to separate buffy-coats and to treat them in vitro with a derivative of cyclophosphamide (ASTA Z 7557). After processing, the volumes of BM suspensions were reduced to 25%. Recoveries of leucocytes, CFUc and BFUe were respectively 62, 85 and 84%. In vitro treatment with doses of ASTA Z ranging from 50 to 140 μg/2× 107 leucocytes (according to the CFUc sensitivity of each patient) destroyed 95 ±5% of initial CFUc. After freezing and thawing, recovery of CFUc from treated BM was poor (24%) in comparison to that obtained with untreated BM (79%).Keywords
This publication has 0 references indexed in Scilit: